Novavax, Inc. (NVAX) Appoints Sven Andreasson As Senior Vice President, Corporate Development
5/7/2014 9:55:47 AM
GAITHERSBURG, Md., May 6, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Sven Andréasson to the position of Senior Vice President, Corporate Development, effective June 2, 2014. Mr. Andréasson will be responsible for identifying, prioritizing and evaluating new strategic opportunities that leverage the company's core strengths and growth initiatives.
Help employers find you! Check out all the jobs and post your resume.
comments powered by